20:58 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Oxford BioDynamics reports data for predicting inadequate responders to methotrexate

Oxford BioDynamics plc (LSE:OBD) and colleagues reported that the presence of a five-marker Chromosome Confirmation Signature (CCS) in the blood of patients with early rheumatoid arthritis as detected by the company's EpiSwitch epigenetic biomarker platform...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
08:00 , Dec 3, 2012 |  BioCentury  |  Regulation

A tale of two adjuvants

The different results from FDA's panel reviews of Q-Pan H5N1 influenza vaccine from GlaxoSmithKline plc and Heplisav HBV vaccine from Dynavax Technologies Corp. provide three clear messages to companies developing adjuvanted vaccines: the larger the...
07:00 , May 2, 2011 |  BC Week In Review  |  Clinical News

Bone Marrow Aspiration Concentrate: Phase I started

Harvest began the open-label, international Phase I REVIVE-1 trial to evaluate a coronary sinus infusion of 60 mL BMAC in about 60 patients. Harvest Technologies Corp., Plymouth, Mass.   Product: Bone Marrow Aspiration Concentrate (BMAC)...
07:00 , May 4, 2009 |  BioCentury  |  Product Development

Adjuvant Technologies

Adjuvant Technologies Company Adjuvant technology Alphavax Inc. Alphavirus RNA replicon vectors Antigenics Inc. (NASDAQ:AGEN) QS-21 purified saponin extract BiondVax Pharmaceuticals Ltd. (Tel Aviv:BNDK) Bacterial protein flagellin...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Company News

NasVax, Protea Vaccine Technologies deal

NasVax plans to acquire fellow vaccine company Protea for cash and stock. NasVax's offer includes $125,000 in cash up front and a second $125,000 payment when Protea closes a separate deal with an undisclosed third...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Clinical News

VaxiSome: Phase I/IIa data

In a double-blind Israeli Phase I/IIa study in 157 healthy volunteers, VaxiSome was well tolerated and did not produce serious adverse events or significant systemic adverse events. The adjuvanted vaccine also produced higher increases in...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Clinical News

VaxiSome: Phase I/IIa started

NasVax began a double-blind, active-controlled, Israeli Phase l/lla trial of single intramuscular doses of VaxiSome in 80 healthy elderly volunteers. NasVax Ltd. (Tel Aviv:NSVX), Ness Ziona, Israel   Product: VaxiSome   Business: Infectious   Molecular target: NA...
07:00 , Oct 29, 2007 |  BC Week In Review  |  Clinical News

OrCel Composite Cultured Skin regulatory update

OTCI completed submission of the final safety and efficacy data portions of a PMA to FDA for OrCel to treat venous leg ulcers. The company filed the chemistry, manufacturing and control (CMC) section of the...
07:00 , Aug 20, 2007 |  BC Week In Review  |  Clinical News

CCS/C-adjuvated influenza vaccine: Phase I/IIa started

NSVX began a double-blind, dose-escalation, Israeli Phase I/IIa trial in 100 healthy volunteers. NasVax Ltd. (Tel Aviv:NSVX), Ness Ziona, Israel   Product: CCS/C-adjuvated influenza vaccine   Business: Infectious   Molecular target: NA   Description: Intramuscular influenza vaccine combined with...